Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics, Inc. (RAPT) Cash from Investing Activities (2020 - 2024)

RAPT Therapeutics' Cash from Investing Activities history spans 5 years, with the latest figure at -$843000.0 for Q4 2024.

  • For Q4 2024, Cash from Investing Activities fell 104.08% year-over-year to -$843000.0; the TTM value through Dec 2024 reached $52.7 million, down 49.39%, while the annual FY2024 figure was $52.7 million, 49.39% down from the prior year.
  • Cash from Investing Activities for Q4 2024 was -$843000.0 at RAPT Therapeutics, down from $18.4 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $32.4 million in Q2 2023 and bottomed at -$63.7 million in Q2 2021.
  • The 5-year median for Cash from Investing Activities is $6.7 million (2020), against an average of -$2.9 million.
  • The largest annual shift saw Cash from Investing Activities crashed 1437.17% in 2021 before it soared 410.16% in 2023.
  • A 5-year view of Cash from Investing Activities shows it stood at $15.5 million in 2020, then crashed by 202.56% to -$15.9 million in 2021, then plummeted by 159.69% to -$41.3 million in 2022, then surged by 150.01% to $20.6 million in 2023, then plummeted by 104.08% to -$843000.0 in 2024.
  • Per Business Quant, the three most recent readings for RAPT's Cash from Investing Activities are -$843000.0 (Q4 2024), $18.4 million (Q3 2024), and $19.2 million (Q2 2024).